2026-01-22 - Analysis Report
**Financial Report: Abbott Laboratories (ABT)**

**Company Overview (in 1 line)**: Abbott Laboratories is a multinational healthcare company that develops and markets a wide range of medical products, including diagnostics, nutritionals, and pharmaceuticals.

**Return Rate Comparison with S&P 500 (VOO)**

* Cumulative return of review stock (ABT): 31.42%
* Cumulative return of comparison stock (S&P 500, VOO): 91.55%
* Divergence (max: 37.10, min: -60.80, current: -60.80, relative divergence: 0.00%)
* ABT's cumulative return is 60.13% lower than VOO's cumulative return.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 32.0% | 14.5% | 28.0% | 1.1 | 125.9B |
| 2017-2019  | 41.0% | 14.5% | 24.0% | 1.0 | 151.2B |
| 2018-2020  | -1.0% | 16.8% | -22.0% | 0.9 | 190.6B |
| 2019-2021  | 42.0% | 16.8% | -2.0% | 0.8 | 244.9B |
| 2020-2022  | -20.0% | 28.8% | -18.0% | 0.8 | 191.1B |
| 2021-2023  | -22.0% | 28.8% | -23.0% | 0.7 | 191.6B |
| 2022-2024  | -31.0% | 24.3% | -50.0% | 0.7 | 196.9B |
| 2023-2025  | 10.0% | 16.0% | -52.0% | 0.3 | 218.1B |

**Recent Stock Price Fluctuations**

* Close: $120.73
* Last-market: {'price': 120.73, 'previousClose': 121.14, 'change': -0.34}
* 5-day SMA: $122.43
* 20-day SMA: $124.68
* 60-day SMA: $125.71

**RSI, PPO Index Indicators**

* Market Risk Indicator (MRI): 0.80
* RSI: 31.47
* PPO: -0.41
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: -2.00 (-): worsening
* 7-day Rank change: 50 (+): rank up
* 7-day Dynamic Expected Return change: 0.80 (+): improving
* Expected Return (%): -1605.30%

**Recent News & Significant Events**

* On 2026-01-21, Vest Financial LLC lifted its stake in Abbott Laboratories (ABT)
* On 2026-01-21, Simplywall.st reported on Abbott Laboratories' medical device and diagnostics momentum
* On 2026-01-21, Seeking Alpha previewed Abbott Laboratories' Q4 2025 earnings report
* On 2026-01-21, Finviz questioned whether analysts think Abbott (ABT) is a good investment
* On 2026-01-06, Yahoo Finance compared PBH and ABT as value options
* On 2026-01-21, MSN previewed Abbott Laboratories' (ABT) Q4 earnings report

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): 144.75 / 169.00 / 122.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|----:|-------:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2025-10-29 | 0.94 | 10.63 B$ |

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

**Comprehensive Analysis (Summary of previous items)**

Based on the provided data, we can conclude that:

* ABT's cumulative return is significantly lower than VOO's cumulative return.
* The company's return rate has been volatile, with a mix of positive and negative returns over the past few years.
* The company's RSI and PPO indicators suggest a sell signal, while the MRI indicates a medium risk level.
* The company's revenue and profitability have been relatively stable, with a slight decrease in profit margin over the past few quarters.
* The company's equity has been increasing, with a slight decrease in ROE over the past few quarters.
* Analyst consensus suggests a buy rating, with a target price range of 122.00 to 169.00.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.